- Home
- UFCS vs MLTX Comparison
UFCS vs MLTX Comparison
Compare UFCS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | MLTX |
|---|---|---|
| Founded | 1946 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UFCS | MLTX |
|---|---|---|
| Price | $48.29 | $19.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $40.50 | $27.50 |
| AVG Volume (30 Days) | 99.5K | ★ 722.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,386,412,000.00 | N/A |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $8.77 | N/A |
| P/E Ratio | $41.68 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $25.81 | $5.95 |
| 52 Week High | $49.94 | $62.75 |
Technical Indicators
Market Signals| Indicator | UFCS | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 58.60 |
| Support Level | $43.01 | $15.54 |
| Resistance Level | $49.94 | $19.24 |
| Average True Range (ATR) | 1.25 | 0.92 |
| MACD | 0.14 | 0.10 |
| Stochastic Oscillator | 88.29 | 70.72 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.